Want to see RVMD full AI Analyst Report?
Top Page
Revolution Medicines
(NASDAQ:RVMD)
Select Model
Select Model
Rating:63Neutral
Price Target:
$225.00
▲(6.44% Upside)
Action:Reiterated
Date:08/26/26
Overall score reflects a strong technical uptrend and highly favorable clinical/regulatory momentum with substantial funding capacity, tempered by very weak and worsening financial performance (large accelerating losses and cash burn) and limited valuation support due to negative earnings and no dividend.
Positive Factors
FDA Approval Creates Commercial Product
RASONQUE approval converts Revolution Medicines from a purely clinical-stage developer into a commercial oncology company. Immediate U.S. availability establishes a potential recurring product-revenue base and validates its RAS(ON) platform.
Negative Factors
Accelerating Cash Burn and Operating Losses
The company is consuming cash rapidly while scaling clinical, manufacturing and commercial operations. Sustained losses of this magnitude could require additional financing, increasing dilution risk and limiting flexibility if product revenue ramps slowly.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA Approval Creates Commercial Product
RASONQUE approval converts Revolution Medicines from a purely clinical-stage developer into a commercial oncology company. Immediate U.S. availability establishes a potential recurring product-revenue base and validates its RAS(ON) platform.
Read all positive factors
Revolution Medicines (RVMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$44.56B
Dividend YieldN/A
Average Volume (3M)2.70M
Price to Earnings (P/E)―
Beta (1Y)1.55
Revenue GrowthN/A
EPS Growth-95.67%
CountryUS
Employees883
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.86
Shares Outstanding214,336,410
10 Day Avg. Volume1,922,310
30 Day Avg. Volume2,704,654
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)9.28
Price to Sales (P/S)0.00
P/FCF Ratio-16.57
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$248.65Price Target Upside17.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)-9.75
Revenue Forecast (FY)$165.82M
Revolution Medicines Business Overview & Revenue Model
Company Description
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising dru...
How the Company Makes Money
Revolution Medicines primarily generates revenue through collaboration and licensing arrangements rather than product sales, because (to the extent publicly available information indicates) it does not have commercial-stage, approved drugs that ge...
Revolution Medicines Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Positive
The call conveyed strong positive clinical and regulatory momentum: a pivotal Phase III PDAC result (published in NEJM) with FDA NDA acceptance, robust expanded access uptake, multiple encouraging lung cancer combination datasets (high ORRs, high DCRs and early durability signals), an advancing global Phase III program across indications, and a healthy balance sheet ($3.9B) to fund commercialization and aggressive development. Offsetting these positives were materially higher operating expenses, a widened quarterly net loss (partly driven by a $151M noncash warrant charge), and remaining uncertainties around European timelines, CRC strategy details (deferred to Q4), and potential trial integrity risks from broad EAP access. On balance, the clinical wins, regulatory progress and financial resources substantially outweigh the increased spend and uncertainties, supporting an overall optimistic view.Positive Updates
Paradigm-Changing Phase III Pancreatic Cancer Results
RASolute 302 Phase III data presented at ASCO and published in The New England Journal of Medicine demonstrated statistically significant and clinically meaningful improvements in overall survival, progression-free survival and patient-reported quality of life for daraxonrasib monotherapy versus chemotherapy in previously treated metastatic pancreatic cancer. The company’s NDA for daraxonrasib in pancreatic cancer has been accepted for review by the U.S. FDA and the EMA initiated an expedited phase review under its Cancer Medicines Pathfinder project.
Negative Updates
Substantial Increase in R&D Spending
R&D expense rose to $395 million in Q2 2026 from $224 million in Q2 2025, an increase of approximately 76.3%, driven by increased clinical trial and manufacturing costs for daraxonrasib and zoldonrasib and higher personnel-related costs.
Read all updates
Q2-2026 Updates
Positive
Negative
Paradigm-Changing Phase III Pancreatic Cancer Results
RASolute 302 Phase III data presented at ASCO and published in The New England Journal of Medicine demonstrated statistically significant and clinically meaningful improvements in overall survival, progression-free survival and patient-reported quality of life for daraxonrasib monotherapy versus chemotherapy in previously treated metastatic pancreatic cancer. The company’s NDA for daraxonrasib in pancreatic cancer has been accepted for review by the U.S. FDA and the EMA initiated an expedited phase review under its Cancer Medicines Pathfinder project.
Read all positive updates
Company Guidance
Revolution Medicines updated 2026 financial guidance, raising expected full‑year GAAP operating expenses to $2.1–$2.2 billion, which includes $270–$290 million of non‑cash stock‑based compensation; the company finished Q2 with $3.9 billion in cash and investments (including $2.2 billion gross proceeds from April offerings and a $250 million second royalty tranche) and up to $1.5 billion of additional committed capital under its Royalty Pharma arrangement. For Q2, R&D expense was $395 million (vs. $224M in Q2 2025), G&A was $110 million (vs. $41M), and net loss was $644 million (vs. $248M), which included a $151 million non‑cash charge for warrant fair‑value remeasurement. Management said the higher 2026 spend is being driven by accelerated manufacturing (commercial and clinical), increased clinical development, and stepped‑up commercial readiness, and provided programmatic timelines including completing enrollment in RASolve 301 this year with an initial readout in 2027, initiating RASolve 307 in Q4 2026, a CRC update in Q4, identifying RMC‑5127 RP2D in H2 2026 and first clinical data for some programs in 2027.Revolution Medicines Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 11.58M | 35.38M | 29.39M |
| Gross Profit | -9.24M | -16.56M | 0.00 | 11.58M | 35.38M | 29.39M |
| EBITDA | -1.70B | -1.09B | -589.02M | -430.28M | -239.47M | -179.75M |
| Net Income | -1.77B | -1.13B | -600.09M | -436.37M | -248.71M | -187.09M |
Balance Sheet | ||||||
| Total Assets | 4.32B | 2.35B | 2.56B | 2.06B | 811.93M | 737.99M |
| Cash, Cash Equivalents and Short-Term Investments | 3.94B | 2.03B | 2.29B | 1.85B | 644.94M | 577.05M |
| Total Debt | 641.93M | 158.70M | 135.84M | 87.94M | 64.20M | 66.63M |
| Total Liabilities | 1.72B | 723.21M | 293.10M | 235.51M | 126.74M | 135.42M |
| Stockholders Equity | 2.61B | 1.63B | 2.27B | 1.83B | 685.19M | 602.57M |
Cash Flow | ||||||
| Free Cash Flow | -1.59B | -913.73M | -567.74M | -358.30M | -235.22M | -153.71M |
| Operating Cash Flow | -1.58B | -897.74M | -557.44M | -350.57M | -224.40M | -147.18M |
| Investing Cash Flow | -1.21B | 118.06M | -554.39M | -342.60M | -24.12M | -142.12M |
| Financing Cash Flow | 3.26B | 621.52M | 959.41M | 1.23B | 301.43M | 294.18M |
Revolution Medicines Technical Analysis
Neutral
211.38
Price Trends
193.65
Positive
170.07
Positive
131.19
Positive
Market Momentum
6.15
Positive
52.34
Neutral
49.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVMD, the sentiment is Neutral. The current price of 211.38 is above the 20-day moving average (MA) of 207.70, above the 50-day MA of 193.65, and above the 200-day MA of 131.19, indicating a neutral trend. The MACD of 6.15 indicates Positive momentum. The RSI at 52.34 is Neutral, neither overbought nor oversold. The STOCH value of 49.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RVMD.
Revolution Medicines Risk Analysis
Revolution Medicines disclosed 85 risk factors in its most recent earnings report. Revolution Medicines reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Revolution Medicines Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
85 Outperform | $25.21B | 15.16 | 29.70% | ― | 26.93% | 80.66% | |
78 Outperform | $13.49B | 16.61 | 42.49% | ― | 9.23% | 53.08% | |
72 Outperform | $19.99B | 25.78 | 14.55% | ― | 21.75% | -36.69% | |
63 Neutral | $44.56B | -23.20 | -96.44% | ― | ― | -95.67% | |
56 Neutral | $25.64B | -13.00 | -9.16% | ― | -1.05% | -395.95% | |
53 Neutral | $4.11B | -11.71 | -42.27% | ― | 23.86% | 19.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
RVMD
Revolution Medicines
205.57
166.04
420.04%
EXEL
Exelixis
54.64
17.46
46.96%
INCY
Incyte
123.22
37.24
43.31%
GMAB
Genmab
33.16
7.27
28.08%
BNTX
BioNTech SE
101.61
0.99
0.98%
RLAY
Relay Therapeutics
18.38
14.72
402.19%
Revolution Medicines Corporate Events
Business Operations and StrategyProduct-Related Announcements
Revolution Medicines Wins FDA Approval for RASONQUE Therapy
Positive
Aug 26, 2026
On August 26, 2026, Revolution Medicines received U.S. Food and Drug Administration approval for RASONQUE, or daraxonrasib, as a once-daily oral treatment for adult patients with metastatic pancreatic adenocarcinoma who have failed at least one pr...
Executive/Board ChangesShareholder Meetings
Revolution Medicines Announces R&D Leadership Transition and Governance Votes
Positive
Jun 22, 2026
On June 18, 2026, Revolution Medicines announced that its president of research and development, Steve Kelsey, M.D., FRCP, FRCPath, plans to retire effective January 4, 2027, and will shift to a senior advisor role to the CEO starting July 1, 2026...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.